How has India responded to SARS-CoV-2 variants?

News Today 27.12.2021

In January, Bharat Biotech, the maker of Covaxin, got an ”emergency use authorisation” from India’s Drugs Controller General, with Covishield, developed by the Serum Institute of India, Pune. Covishield was based on the ChAdOx1 vaccine made by Oxford University and had been approved in the U.K. after phase-3 clinical trial results. For Covaxin, phase-3 trials were still underway and regulators approved it largely on data from phase-1 and phase-2 trials that showed it was safe and produced an immunogenic reaction. The rush for vaccines was propelled by a need to inoculate India’s frontline doctors and nurses followed by the rest of the adult population. (Read More)


Be the first to comment

Leave a Reply

Your email address will not be published.